Patients with endometriosis in the vagina, bowel, or bladder experience a prolonged diagnostic delay: an observational study

Mette Madsen, Hartwell D, D. Hartwell, L K A Kähler, Kähler LKA, Lise K. A. Kähler, Dyrved L, L Dyrved, Ejsing BH, B H Ejsing, Benedikte Holm Ejsing, Vexø LE, Laura Emilie Vexø, L E Vexø, Sofie E. Thomassen, S E Thomassen, Thomassen SE, M C Havemann, Havemann MC, Maria Cecilie Havemann, A. Sakse, A E Sakse, Sakse AE, K Røssaak, Røssaak K, Mette Nyegaard, Henriette Svarre Nielsen
Human Reproduction · 2025 · vol. 40(5) , pp. 834–842 · doi:10.1093/humrep/deaf046 · PMID:40127638 · W4408845901
Observational OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Endometriosis involving the vagina, intestine, or bladder was associated with a significantly longer diagnostic delay, earlier symptom onset, and more severe menstrual pain compared to other endometriosis presentations.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

STUDY QUESTION: Do the diagnostic delay and symptoms differ between endometriosis patients with advanced disease, defined as endometriosis involving the vagina, intestine, rectovaginal septum, or bladder (eVIRB), compared to patients without endometriosis in these locations (non-eVIRB)? SUMMARY ANSWER: Patients with advanced endometriosis had a significantly longer diagnostic delay, an earlier onset of symptoms, and more intense pain during menstruation. WHAT IS KNOWN ALREADY: Endometriosis patients often experience years of symptoms before diagnosis. Whether there is an association between the length of this diagnostic delay and advanced disease remains unclear. Confirming such an association would underscore the importance of early diagnosis to ensure appropriate treatment, which may reduce the risk of irreversible organ damage and high-risk surgery for patients. STUDY DESIGN, SIZE, DURATION: This is an observational cohort study of 129 patients undergoing endometriosis surgery conducted over a 3-year period. The first patient was operated on in November 2019. All patients reported retrospective questionnaire data, and surgeons described surgical findings. PARTICIPANTS/MATERIALS, SETTING, METHODS: The patients were operated on for predominantly moderate to severe endometriosis at a Tertiary Endometriosis Centre in Denmark. The diagnostic delay was calculated from questionnaire data and related to intraoperative findings. Selected symptoms were compared. MAIN RESULTS AND THE ROLE OF CHANCE: The median diagnostic delay was 5 years. However, the patients with eVIRB (n = 75) experienced a significantly longer median diagnostic delay of 9 years compared to non-eVIRB patients (n = 54), who had a median delay of only 2 years (P = 0.005). The odds ratio of having eVIRB was 5-fold (95% CI 2.18-11.61, P < 0.001) increased if the diagnostic delay exceeded 5 years, and they reported a significantly earlier onset of endometriosis symptoms. Both groups reported numerous pain symptoms, with a significant difference observed only in responses regarding severe period cramps requiring bed rest and use of painkillers. The eVIRB group had used hormones significantly longer and had taken painkillers more regularly due to pelvic pain. LIMITATIONS, REASONS FOR CAUTION: The retrospective data may be affected by recall bias. This study describes associations between a prolonged diagnostic delay and advanced disease, not causality. WIDER IMPLICATIONS OF THE FINDINGS: This study is the first to describe an association between advanced endometriosis and a prolonged diagnostic delay after adjusting for total years of hormonal use and age at surgery. Future research should concentrate on strategies to achieve earlier diagnosis for patients presenting with this advanced form of the disease, given the potential for severe complications. STUDY FUNDING/COMPETING INTEREST(S): Ferring Pharmaceuticals (MiHSN01) and partial funding from The European Union's Horizon 2020 research and innovation programme (No. 101017562). None of the funders was involved in the study design, data collection, analysis, writing of this paper, or the decision to submit it for publication. H.S.N. reports speakers' fees from Ferring Pharmaceuticals, Merck Denmark A/S, IBSA Nordic, AstraZeneca, Cook Medical, Gedeon Richter, and Novo Nordisk outside the submitted work. No other conflicts are reported. TRIAL REGISTRATION NUMBER: N/A.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis Delayed Diagnosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (42)

Cited by (1)

Source provenance

europepmc
last seen: 2026-10-13T06:10:10.580696+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-13T06:07:10.018355+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK